claim: ruxolitinib rapidly cause acute respiratory distress syndrome in covid-19 disease.
evidence_1: ruxolitinib can be a therapeutic option for patients with respiratory insufficiency in covid-19 related ards.", "despite the limited number of patients collected, the results obtained are encouraging and indicate ruxolitinib as a potential therapeutic option for patients with severe covid-19 related respiratory insufficiency.", "based on these considerations, we hypothesized that immune- modulation with ruxolitinib might have been beneficial in reducing severity of ards in the context of covid-19."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )